Your browser doesn't support javascript.
loading
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
Williams, Wilton B; Liao, Hua-Xin; Moody, M Anthony; Kepler, Thomas B; Alam, S Munir; Gao, Feng; Wiehe, Kevin; Trama, Ashley M; Jones, Kathryn; Zhang, Ruijun; Song, Hongshuo; Marshall, Dawn J; Whitesides, John F; Sawatzki, Kaitlin; Hua, Axin; Liu, Pinghuang; Tay, Matthew Z; Seaton, Kelly E; Shen, Xiaoying; Foulger, Andrew; Lloyd, Krissey E; Parks, Robert; Pollara, Justin; Ferrari, Guido; Yu, Jae-Sung; Vandergrift, Nathan; Montefiori, David C; Sobieszczyk, Magdalena E; Hammer, Scott; Karuna, Shelly; Gilbert, Peter; Grove, Doug; Grunenberg, Nicole; McElrath, M Juliana; Mascola, John R; Koup, Richard A; Corey, Lawrence; Nabel, Gary J; Morgan, Cecilia; Churchyard, Gavin; Maenza, Janine; Keefer, Michael; Graham, Barney S; Baden, Lindsey R; Tomaras, Georgia D; Haynes, Barton F.
Afiliación
  • Williams WB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu wilton.williams@duke.edu.
  • Liao HX; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Moody MA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Kepler TB; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA.
  • Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Gao F; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Trama AM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Jones K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Zhang R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Song H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Marshall DJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Whitesides JF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Sawatzki K; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA.
  • Hua A; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA.
  • Liu P; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Tay MZ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Seaton KE; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Shen X; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Foulger A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Lloyd KE; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Parks R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Pollara J; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Yu JS; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Vandergrift N; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Sobieszczyk ME; Department of Medicine, Columbia University Medical Center, New York, NY, USA.
  • Hammer S; Department of Medicine, Columbia University Medical Center, New York, NY, USA.
  • Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gilbert P; The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Grove D; The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Nabel GJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Morgan C; The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Churchyard G; The Aurum Institute, Johannesburg, South Africa.
  • Maenza J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Keefer M; University of Rochester School of Medicine, Rochester, NY, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Baden LR; Brigham and Women's Hospital, Boston, MA, USA.
  • Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu wilton.williams@duke.edu.
Science ; 349(6249): aab1253, 2015 Aug 14.
Article en En | MEDLINE | ID: mdl-26229114
ABSTRACT
An HIV-1 DNA prime vaccine, with a recombinant adenovirus type 5 (rAd5) boost, failed to protect from HIV-1 acquisition. We studied the nature of the vaccine-induced antibody (Ab) response to HIV-1 envelope (Env). HIV-1-reactive plasma Ab titers were higher to Env gp41 than to gp120, and repertoire analysis demonstrated that 93% of HIV-1-reactive Abs from memory B cells responded to Env gp41. Vaccine-induced gp41-reactive monoclonal antibodies were non-neutralizing and frequently polyreactive with host and environmental antigens, including intestinal microbiota (IM). Next-generation sequencing of an immunoglobulin heavy chain variable region repertoire before vaccination revealed an Env-IM cross-reactive Ab that was clonally related to a subsequent vaccine-induced gp41-reactive Ab. Thus, HIV-1 Env DNA-rAd5 vaccine induced a dominant IM-polyreactive, non-neutralizing gp41-reactive Ab repertoire response that was associated with no vaccine efficacy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Anticuerpos Anti-VIH / Proteína gp41 de Envoltorio del VIH / VIH-1 / Vacunas contra el SIDA / Vacunas de ADN / Microbiota Límite: Humans Idioma: En Revista: Science Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Asunto principal: Anticuerpos Anti-VIH / Proteína gp41 de Envoltorio del VIH / VIH-1 / Vacunas contra el SIDA / Vacunas de ADN / Microbiota Límite: Humans Idioma: En Revista: Science Año: 2015 Tipo del documento: Article